Irene Andrulis

Personal Home Page

http://www.mshri.on.ca/?page=Dr. Irene Andrulis

Articles in Scholarly Journals [Incomplete List]

  1. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
    BMC Cancer, vol. 8, no. 1, p. 6, 2008
  2. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer
    Breast Cancer Research, vol. 9, no. 6, p. 215, 2007
  3. Expression of the Circadian Clock Genes Per1 and Per2 in Sporadic and Familial Breast Tumors
    Neoplasia, vol. 9, no. 10, pp. 797–800, 2007
  4. BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays
    The American Journal of Surgical Pathology, vol. 31, no. 1, pp. 121–128, 2007
  5. Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women
    Clinical Genetics, vol. 72, no. 2, pp. 87–97, 2007
  6. AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study
    Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 7, pp. 1416–1421, 2007
  7. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors
    BMC Cancer, vol. 7, no. 1, p. 85, 2007
  8. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
    BMC Cancer, vol. 7, no. 1, p. 99, 2007
  9. COPS3 amplification and clinical outcome in osteosarcoma
    Cancer, vol. 109, no. 9, pp. 1870–1876, 2007
  10. Medical radiation exposure and breast cancer risk: Findings from the Breast Cancer Family Registry
    International Journal of Cancer, vol. 121, no. 2, pp. 386–394, 2007
  11. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer
    Breast Cancer Research and Treatment, vol. 105, no. 3, pp. 255–265, 2007
  12. Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry
    Breast Cancer Research and Treatment, vol. 106, no. 2, pp. 281–288, 2007
  13. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer
    Breast Cancer Research and Treatment, 2007
  14. Identification of rare variants in the hLIMD1 gene in breast cancer
    Cancer Genetics and Cytogenetics, vol. 178, no. 1, pp. 36–41, 2007
  15. RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies
    The American Journal of Human Genetics, vol. 81, no. 6, pp. 1186–1200, 2007
  16. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
    New England Journal of Medicine, vol. 354, no. 20, pp. 2103–2111, 2006
  17. Functional characterization of novel presenilin-2 variants identified in human breast cancers
    Oncogene, vol. 25, no. 25, Article ID 1209397, 7 pages, 2006
  18. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study
    Breast Cancer Research and Treatment, vol. 105, no. 1, pp. 69–80, 2006
  19. Sedimentary Characteristics and Reservoir Prediction of Paleogene in the East Part of Kuqa Foreland Basin
    Journal of China University of Geosciences, vol. 17, no. 2, pp. 138–157, 2006
  20. Application of reliability coefficients in cDNA microarray data analysis
    Statistics in Medicine, vol. 25, no. 6, pp. 1051–1066, 2006
  21. A genome wide linkage search for breast cancer susceptibility genes
    Genes, Chromosomes and Cancer, vol. 45, no. 7, pp. 646–655, 2006
  22. Genomic alterations in lobular neoplasia: A microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast
    Genes, Chromosomes and Cancer, vol. 45, no. 11, pp. 1007–1017, 2006
  23. Population-based estimates of breast cancer risks associated withATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry
    Human Mutation, vol. 27, no. 11, pp. 1122–1128, 2006
  24. BMC Cancer, vol. 6, no. 1, p. 114, 2006
  25. The CHEK2*1100delC Allelic Variant and Risk of Breast Cancer: Screening Results from the Breast Cancer Family Registry
    Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 2, pp. 348–352, 2006
  26. The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 1, pp. 76–79, 2006
  27. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
    Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 10, pp. 1863–1870, 2006
  28. No Increased Risk of Breast Cancer Associated with Alcohol Consumption among Carriers of BRCA1 and BRCA2 Mutations Ages <50 Years
    Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 8, pp. 1565–1567, 2006
  29. The c-Myc Oncogene Directly Induces the H19 Noncoding RNA by Allele-Specific Binding to Potentiate Tumorigenesis
    Cancer Research, vol. 66, no. 10, pp. 5330–5337, 2006
  30. Constitutive Hedgehog Signaling in Chondrosarcoma Up-Regulates Tumor Cell Proliferation
    American Journal Of Pathology, vol. 168, no. 1, pp. 321–330, 2006
  31. Breast Cancer Research, vol. 8, no. 4, p. R44, 2006
  32. TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
    Journal of Clinical Oncology, vol. 23, no. 7, pp. 1483–1490, 2005
  33. Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations
    Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 2, pp. 350–356, 2005
  34. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer
    Journal of Medical Genetics, vol. 42, no. 8, pp. 633–638, 2005
  35. Altered expression and deletion ofRMO1 in osteosarcoma
    International Journal of Cancer, vol. 114, no. 5, pp. 738–746, 2005
  36. LAF-4 is aberrantly expressed in human breast cancer
    International Journal of Cancer, vol. 115, no. 4, pp. 568–574, 2005
  37. An inverse association between ovarian cysts and breast cancer in the breast cancer family registry
    International Journal of Cancer, vol. 118, no. 1, pp. 197–202, 2005
  38. Prognostic factors affecting the natural history of node-negative breast cancer
    Breast Cancer Research and Treatment, vol. 89, no. 1, pp. 35–45, 2005
  39. Invasive lobular carcinoma: to grade or not to grade
    Modern Pathology, vol. 18, no. 5, Article ID 3800273, 7 pages, 2005
  40. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast
    Modern Pathology, vol. 18, no. 6, Article ID 3800362, 10 pages, 2005
  41. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
    British Journal of Cancer, vol. 91, no. 11, Article ID 6602239, 4 pages, 2004
  42. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
    The Women's Oncology Review, vol. 4, no. 2, pp. 131–132, 2004
  43. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
    Cancer Cell, vol. 6, no. 4, pp. 387–398, 2004
  44. von Willebrand factor expression in osteosarcoma metastasis
    Modern Pathology, vol. 18, no. 3, Article ID 3800265, 9 pages, 2004
  45. Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire
    Annals of Epidemiology, vol. 14, no. 1, pp. 36–43, 2004
  46. Amplification of theTOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
    Genes, Chromosomes and Cancer, vol. 39, no. 4, pp. 288–297, 2004
  47. Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry
    Cancer Epidemiology Biomarkers & Prevention, vol. 13, no. 1, pp. 146–149, 2004
  48. Breast Cancer Research, vol. 6, no. 4, p. R375, 2004
  49. The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer
    Journal of Clinical Oncology, vol. 22, no. 1, pp. 86–96, 2003
  50. Cloning and mutation analysis of ZFP276 as a candidate tumor suppressor in breast cancer
    Journal of Human Genetics, vol. 48, no. 12, pp. 668–671, 2003
  51. Reduced growth of human sarcoma xenografts in hosts homozygous for thelit mutation
    Journal of Surgical Oncology, vol. 81, no. 2, pp. 75–79, 2002
  52. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry
    Cancer, vol. 95, no. 10, pp. 2068–2075, 2002
  53. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases
    Human Mutation, vol. 20, no. 1, pp. 28–34, 2002
  54. Comparison of DNA- and RNA-Based Methods for Detection of TruncatingBRCA1 Mutations
    Human Mutation, vol. 20, no. 1, pp. 65–73, 2002
  55. Characteristics Associated with Participation at Various Stages at the Ontario Site of the Cooperative Family Registry for Breast Cancer Studies
    Annals of Epidemiology, vol. 12, no. 1, pp. 27–33, 2002
  56. From the Cover: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium
    Proceedings of the National Academy of Sciences, vol. 99, no. 2, pp. 827–831, 2002
  57. A mutant PTH/PTHrP type I receptor in enchondromatosis
    Nature Genetics, vol. 30, no. 3, pp. 306–310, 2002
  58. p53 missense but not truncation mutations are associated with low levels of p21CIP1/WAF1mRNA expression in primary human sarcomas
    British Journal of Cancer, vol. 84, no. 12, pp. 1635–1639, 2001
  59. p53 Missense Mutations in Microdissected High-Grade Ductal Carcinoma In Situ of the Breast
    Journal of the National Cancer Institute, vol. 93, no. 9, pp. 700–704, 2001
  60. The Cooperative Familial Registry for Breast Cancer Studies design and first year recruitment rates in Ontario
    Journal of Clinical Epidemiology, vol. 54, no. 1, pp. 93–98, 2001
  61. Breast Cancer Research and Treatment, vol. 65, no. 2, pp. 111–118, 2001
  62. Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
    Cancer, vol. 92, no. 8, pp. 2181–2189, 2001
  63. Comparison of HER2/neu Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry
    American Journal of Clinical Pathology, vol. 115, no. 4, pp. 504–511, 2001
  64. Canadian Sarcoma GroupWorkshop Sarcomas: Molecular Markers to Therapeutics, 26–27 February 2000,Toronto, Canada
    Sarcoma, vol. 4, no. 1-2, pp. 67–73, 2000
  65. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations
    Human Mutation, vol. 16, no. 1, pp. 88–89, 2000
  66. Factors Affecting Distant Disease-Free Survival for Primary Invasive Breast Cancer: Use of a Log-Normal Survival Model
    Annals of Surgical Oncology, vol. 7, no. 6, pp. 416–426, 2000
  67. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2
    Clinical Genetics, vol. 57, no. 5, pp. 376–383, 2000
  68. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens
    Carcinogenesis, vol. 21, no. 9, pp. 1761–1765, 2000
  69. Familial Posterior Fossa Brain Tumors of Infancy Secondary to Germline Mutation of the [ITAL]hSNF5[/ITAL] Gene
    The American Journal of Human Genetics, vol. 66, no. 4, pp. 1403–1406, 2000
  70. British Journal of Cancer, vol. 83, no. 6, pp. 737–742, 2000
  71. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
    Oncogene, vol. 18, no. 3, pp. 783–788, 1999
  72. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer
    Oncogene, vol. 18, no. 32, pp. 4643–4646, 1999
  73. Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations
    Journal of the National Cancer Institute, vol. 91, no. 5, pp. 469–473, 1999
  74. Expression of osteocalcin and its transcriptional regulatorscore-binding factor alpha 1 andMSX2 in osteoid-forming tumours
    Journal of Orthopaedic Research, vol. 17, no. 5, pp. 633–638, 1999
  75. Mutation in the coding region of theBRCA1 gene leads to aberrant splicing of the transcript
    Human Mutation, vol. 14, no. 6, pp. 540–541, 1999
  76. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma
    Journal of Surgical Oncology, vol. 69, no. 1, pp. 21–27, 1998
  77. Preferential allelic expression can lead to reduced expression ofBRCA1 in sporadic breast cancers
    International Journal of Cancer, vol. 77, no. 1, pp. 1–6, 1998
  78. Nature Genetics, vol. 20, no. 1, pp. 13–14, 1998
  79. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients
    Nature Genetics, vol. 16, no. 1, Article ID ng0597-17, 1 pages, 1997
  80. MADR2 Maps to 18q21 and Encodes a TGF??Regulated MAD?Related Protein That Is Functionally Mutated in Colorectal Carcinoma
    Cell, vol. 86, no. 4, pp. 543–552, 1996
  81. SAS is amplified predominantly in surface osteosarcoma
    Journal of Orthopaedic Research, vol. 14, no. 5, pp. 700–705, 1996
  82. Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation
    Human Genetics, vol. 98, no. 3, pp. 310–312, 1996
  83. Correlation of p-Glycoprotein Detection by Immunohistochemistry with mdr-l mRNA Levels in Osteosarcomas Pilot Study
    Diagnostic Molecular Pathology, vol. 4, no. 1, pp. 59–65???65, 1995
  84. Expression of the multidrug resistance gene in osteosarcoma: A pilot study
    Journal of Orthopaedic Research, vol. 11, no. 3, pp. 396–403, 1993
  85. Overexpression of asparagine synthetase in albizziin-resistant murine diploid embryonic stem cells
    Somatic Cell and Molecular Genetics, vol. 19, no. 4, pp. 321–330, 1993
  86. CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations
    Journal of Cellular Physiology, vol. 148, no. 3, pp. 414–420, 1991
  87. Molecular and genetic characterization of human cell lines resistant tol-asparaginase and albizziin
    Somatic Cell and Molecular Genetics, vol. 16, no. 1, pp. 59–65, 1990
  88. Quantitative Analysis of MDR1 (Multidrug Resistance) Gene Expression in Human Tumors by Polymerase Chain Reaction
    Proceedings of the National Academy of Sciences, vol. 87, no. 18, pp. 7160–7164, 1990
  89. Fine structure analysis of the Chinese hamster AS gene encoding asparagine synthetase
    Gene, vol. 80, no. 1, pp. 75–85, 1989
  90. Molecular structure of the human asparagine synthetase gene*1
    Genomics, vol. 4, no. 3, pp. 259–265, 1989
  91. Histidyl-tRNA synthetase of Chinese hamster ovary cells contains phosphoserine
    Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol. 869, no. 2, pp. 215–217, 1986
  92. Molecular cloning of a cDNA for Chinese hamster ovary asparagine synthetase
    Gene, vol. 30, no. 1-3, pp. 1–9, 1984
  93. Isolation and characterization of Chinese hamster ovary cell mutants resistant to the amino acid analog?-aspartyl hydroxamate
    Somatic Cell Genetics, vol. 8, no. 4, pp. 533–545, 1982
  94. Dna-Mediated Gene Transfer of   -aspartylhydroxamate Resistance into Chinese Hamster Ovary Cells
    Proceedings of the National Academy of Sciences, vol. 78, no. 9, pp. 5724–5728, 1981